Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 185Neoplasms 11Prostate Adenocarcinoma 3Neoplasm Metastasis 3Adenocarcinoma 2Urogenital Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Recurrence 1Prostatic Diseases 1Primary Dysautonomias 1PSA Level Greater Than Two 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Lymphatic Metastasis 1Lower Urinary Tract Symptoms 1Kidney Diseases 1Hypertension 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1Castration-resistant Prostate Cancer Patients with Oligometastases 1Carcinoma 1Advanced Prostate Cancer 1Advanced Prostate Adenocarcinoma 1

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castration-resistant Prostate Cancer Patients with Oligometastases × Leuprolide × Genitourinary × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡